2010

1. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: A phase I-II study by the Spanish group for research on sarcomas

   Cancer, Vol. 116, Núm. 15, pp. 3692-3701